# Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

> **NCT00267514** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 31 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)
- **DRUG:** sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)

## Key facts

- **NCT ID:** NCT00267514
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2015-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267514, "Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00267514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*